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Abstract
Background—The association of atherosclerotic features with first acute coronary syndromes 
(ACS) has not accounted for plaque burden.
Objectives—To identify atherosclerotic features associated with precursors of ACS.
Methods—We performed a nested case:control study within a cohort of 25,251 patients 
undergoing coronary computed tomographic angiography (CCTA) with follow-up over 3.4±2.1 
years. ACS patients and non-events with no prior coronary artery disease (CAD) were propensity 
matched 1:1 for risk factors and CCTA-evaluated obstructive (≥50%) CAD. Separate core labs 
performed blinded adjudication of ACS and culprit lesions and quantification of baseline CCTA 
for % diameter stenosis (%DS), % cross-sectional plaque burden (PB), plaque volumes (PV) by 
composition (calcified, fibrous, fibro-fatty, and necrotic core), and presence of high-risk plaques 
(HRP).
Results—We identified 234 ACS and control pairs (62 years, 63% male). Over 65% of ACS 
patients had non-obstructive CAD at baseline, and 52% had HRP. %DS, cross-sectional PB, fibro-
fatty and necrotic core volume, and HRP increased the adjusted hazard ratio (HR) of ACS [1.010 
per %DS, 95% confidence interval (CI) 1.005–1.015; 1.008 per % cross-sectional PB, 95% CI 
1.003–1.013; 1.002 per mm3 fibro-fatty plaque, 95% CI 1.000–1.003; 1.593 per mm3 necrotic 
core, 95%CI 1.219–2.082; all p <0.05]. Of the 129 culprit lesion precursors identified by CCTA, 
three-fourths exhibited <50% stenosis and 31.0% exhibited HRP.
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Conclusion—Although ACS increases with %DS, most precursors of ACS cases and culprit 
lesions are non-obstructive. Plaque evaluation, including HRP, PB, and plaque composition, 
identifies high risk patients above and beyond stenosis severity and aggregate plaque burden.
Keywords
Coronary artery disease; acute coronary syndrome; coronary computed tomography angiography; 
atherosclerosis; clinical outcome
Introduction
Prior invasive and pathologic studies have identified coronary atherosclerotic plaque features 
that are central to the pathogenesis of acute coronary syndromes (ACS) (1,2). These include 
measures of coronary luminal narrowing, plaque burden, arterial remodeling, and plaque 
composition including thin cap fibroatheroma, necrotic core and spotty calcification (2–6). 
However, these findings have been largely derived from atherosclerotic evaluation 
simultaneous or subsequent to ACS, to partial samples of the coronary artery tree, and to 
secondary prevention populations (3–5). The utility of vulnerable plaque evaluation in 
comparison to overall atherosclerotic disease burden has been debated, especially given the 
technical difficulty of invasive plaque characterization (7).
Coronary computed tomography angiography (CCTA) is a non-invasive test that enables 
evaluation of all coronary arteries and their branches in patients with suspected or known 
coronary artery disease (CAD). The high accuracy of CCTA for detection and exclusion of 
CAD is well reported, and recent advances in CT technologies now allow for coronary 
atherosclerotic quantification and characterization with high diagnostic performance when 
compared to invasive reference standards (8,9). Limited studies have employed CCTA to 
identify atherosclerotic plaque features associated with ACS (9,10). To date, these studies 
have used non-standardized image analysis protocols, non-quantitative methods, mixed 
populations of patients with and without known CAD, smaller and largely single-center 
studies, and cohorts with few events (4,9–11).
As CCTA is routinely performed in those with suspected but without manifest CAD, it offers 
a unique opportunity to describe the natural history of atherosclerosis in a primary 
prevention population of stable patients before ACS occurrence, whilst accounting for the 
totality of atherosclerotic features in all coronary arteries and their branches at the patient 
level (11,12). We aimed to elucidate the prognostic significance of coronary atherosclerosis 
plaque features for identification of stable patients who will experience future ACS from a 
nested case:control study within a large international multicenter cohort of 25,251 
consecutive patients without known CAD undergoing CCTA (13).
Methods
Study Design and Study Population
The ICONIC (Incident COroNary Syndromes Identified by Computed Tomography) study is 
a nested case:control study of patients without known CAD within the dynamic CONFIRM 
registry, a longitudinal observational cohort study of consecutive individuals undergoing 
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CCTA (13). From this registry, 13 sites from eight countries (the United States, Canada, 
Germany, Austria, Italy, the Netherlands, Portugal, and South Korea) collected consecutive 
patients with baseline CCTA for a total of 25,416 patients with follow-up for 99.6% over 3.4 
± 2.1 years for all-cause mortality and 95.4% over 3.4 ± 2.1 years for MACE events (Figure 
1, Online Appendix I). Physicians or nurses at each site prospectively collected CAD history 
and risk factors, and symptoms at the time of baseline CCTA, coded CCTA stenosis severity 
by segment then collected site adjudication of ACS and death. In the present study, patients 
were eligible if they had had no prior CAD, as defined by no prior revascularization or 
myocardial infarction, and baseline CCTA with follow-up of ACS. Patients with deaths 
without antecedent ACS were censored (Figure 1, Online Appendix II). Candidate patients 
experiencing site-adjudicated ACS were matched 1:1 to within-site controls who did not 
experience ACS. Sites submitted supporting data for ACS, as well as baseline CCTA images, 
for cases and controls. Each site obtained local institutional review board or ethics board 
approval and submitted study ID-coded data stripped of protected health information for 
central adjudication and CCTA measurement.
The Clinical and Data Coordinating Center (CDCC) at the Dalio Institute of Cardiovascular 
Imaging performed uniform adjudication of ACS masked to CCTA evaluation using 
definitions set forth by the World Health Organization (WHO) (14). The CCTA Core 
Laboratory (CCTA-CL) at Severance Hospital of Yonsei University performed 
comprehensive and quantitative analysis of CCTAs blinded to case status. The final study 
population consisted of CDCC-adjudicated ACS and their paired within-site controls that 
had CCTA-CL measured baseline CCTA.
Among 25,251 patients with follow-up for MACE events (804 site-reported ACS, 3.2%) at 
13 sites over 3.4 ± 2.1 years, 2451 patients (221 site-reported ACS) were excluded for prior 
CAD or death without ACS, leaving 22,800 (583 site-reported ACS) eligible for the study. 
After exclusion of site-reported ACS with insufficient or absent clinical data (n=181), with 
ACS in an interval revascularized coronary segment (n=29), with adjudication by the CDCC 
as not meeting criteria for ACS (n=19), without CCTA data to submit to the CL (n=95), or 
with CCTA data that was not interpretable for CL measurements (n=25), the final ICONIC 
study cohort comprised of 234 ACS cases and 234 propensity-matched controls (Figure 1).
Propensity Score Matching
Matching factors were determined a priori and all variables forced into propensity scoring 
using logistic regression were used to predict ACS in the main model. Factors entered into 
propensity scoring procedures included age, male sex, hypertension, hyperlipidemia, 
diabetes mellitus, family history of premature CAD, current smoking, and CAD severity 
assessed by CCTA, defined as non-obstructive, one-vessel, two-vessel, or three-vessel/left 
main disease at the 50% diameter stenosis threshold (area under the receiver-operating curve 
0.94, 95% confidence interval (CI) 0.92–0.95, Online Appendix III). A nearest-neighbor 
approach using 1:1 matching was performed on site and propensity score with a greedy 
matching technique to match all cases. Relaxed models for missing variables were utilized to 
allow all cases to be matched regardless of missing data (15).
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ACS Event Adjudication
The CDCC reviewed ACS event data including cardiac enzyme measurement, 
electrocardiograms and invasive coronary angiograms (ICA) blinded to CCTA data; and 
adjudicated ACS using the WHO/MONICA universal definition of myocardial infarction 
(Online Appendix IV) (14,16). For ACS cases that underwent ICA at the time of ACS, one 
culprit lesion per patient was adjudicated blinded to CCTA data using the modified 
ROMICAT definition and coded using a modified Society of Cardiovascular Computed 
Tomography (SCCT) 18-segment coronary tree (Online Appendix V) (11). ACS cases with 
culprit lesions in interval revascularized segments were excluded.
Among 234 patients with adjudicated ACS, 32 patients were excluded for absence of ICA 
performance, 26 patients were excluded for unavailable ICA to adjudicate a culprit lesion, 
and 14 patients underwent ICA with no culprit lesion that could be determined, leaving 162 
patients with adjudicated culprit lesions. The 72 ACS cases without adjudicated culprits did 
not differ from the 162 cases with adjudicated culprits in age, sex, and type of ACS but did 
exhibit fewer lesions and lesser %DS (Online Appendix, Table VII-4).
Baseline CCTA Analysis
Baseline CCTA performance and site interpretation was performed using CT scanners of 
≥64-detector rows in direct accordance with SCCT guidelines (12,17). The CCTA-CL 
analyzed site-submitted DICOM files masked to clinical results and case status. Independent 
level III-experienced readers at the CCTA-CL performed standardized measurements using 
semiautomated plaque analysis software (QAngioCT Research Edition v2.1.9.1; Medis 
Medical Imaging Systems, Leiden, the Netherlands (Central Illustration) with appropriate 
manual correction (18).
Briefly, for each segment of the 18-segment SCCT model with a diameter ≥2 mm (Online 
Appendix VI), quantitative analysis was performed on every 1-mm cross-section to measure 
vessel length, volume, plaque volume (PV), mean plaque burden (PB), and plaque 
composition using predefined Hounsfield units (HU) thresholds: necrotic core (−30 to 30), 
fibro-fatty (30–130), fibrous (131–350) and calcified plaque (≥350) (12,19). The 
interobserver and intraobserver intraclass correlation for total plaque volume was 0.992 and 
0.996 (p<0.001 respectively). The interobserver and intraobserver intraclass correlation for 
plaque composition ranged from 0.95–0.99 (Online Appendix, Table VI-1).
Additionally, for each lesion, measurements were performed of length, volume and plaque 
composition, as well as percent diameter stenosis (%DS), area stenosis, minimum luminal 
diameter, minimum luminal area, cross-sectional PB, mean PB, and remodeling index 
(Online Appendix VI) (20). Cutpoints of ≥50% and ≥70% %DS were used for obstructive 
CAD. Binary evaluation of adverse plaque characteristics included positive remodeling 
(PR), low attenuation plaque (LAP), spotty calcification (SC), bifurcation, and tortuosity. 
High-risk plaque (HRP) was defined as the presence within a coronary lesion of ≥2 features 
including PR, LAP, or SC (9,10). Segment-based plaque volumes and lesion-based 
measurements were summarized to the patient level, and diffuseness of atherosclerosis 
calculated as the ratio of summed lesion lengths and total vessel length.
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Subsequent to CCTA-CL analysis, ICA-identified culprit lesions were co-registered to the 
baseline CCTA precursor lesions (D.H. and F.Y.L.) by comparison of coronary segment 
coding and using distance from ostia and coronary vessel branch points as fiduciary 
landmarks. Unblinded comparison of ICA and CCTA was allowed for alignment of lesions 
but not for reclassification of ACS.
Statistical Analysis
At the patient level, ACS patients were compared 1:1 to matched patients who did not 
experience ACS. At the lesion level, culprit lesion precursors were compared: 1) within-
subject, to all remaining non-culprit lesions in the same ACS patient; 2) within-subject, to 
the non-culprit lesion with the highest %DS in the same ACS patient; and 3) between-
subject, to the lesion with the highest %DS in the paired control non-ACS patient.
Continuous variables are expressed as means ± standard deviation, and categorical variables 
are presented as absolute counts and percentages. Differences between categorical variables 
were analyzed using McNemar’s test or chi-square test, as appropriate, and those between 
continuous variables using paired Wilcoxon Rank-sum.
Multivariate marginal Cox models adjusting for conventional clinical risk factors were 
employed to compare atherosclerotic plaque differences accounting for propensity matching 
between cases and controls (21). The robust variance estimator accounts for the clustering 
within matched pairs. For per-lesion level analysis, marginal Cox regression was used to 
account for patient effects (22,23). Components of the propensity score were not candidates 
for multivariate regression.
A p value <0·05 was considered to indicate a statistically significant difference. All analyses 
were performed with SAS (version 9.4, SAS Institute Inc., Cary, NC, USA) and R 3.3.0 (R 
Development Core Team, 2016).
Results
Baseline Patient Characteristics and Clinical Events
The final ICONIC study cohort comprised of 234 CDCC-adjudicated ACS cases and 234 
propensity-matched controls with CCTA-CL measured baseline CCTA. The average age of 
the nested case:control cohort was 62.2 ± 11.5 years (63% male) with follow-up time of 3.9 
± 2.5 years. ACS and control patients were well matched by propensity score (0.07 ± 0.04 
vs. 0.07 ± 0.04, p=0.73). ACS cases had lower rates of diabetes mellitus, a component of the 
propensity score (19.7% vs. 31.6%; p<0.001), and greater angina severity (p = 0.004, Online 
Appendix VII). Otherwise, there were no differences in baseline clinical risk factors, 
medications and lipid profiles.
ACS events comprised of 40 ST-elevation myocardial infarctions (STEMI), 114 non-
STEMIs, 6 MIs wherein STEMI and NSTEMI could not be distinguished due to the timing 
of electrocardiogram relative to the ACS, and 74 cases of unstable angina pectoris. Culprit 
lesion precursors were identified by both ICA and baseline CCTA in 129 (53.4%) patients. 
During follow-up, ACS patients more frequently experienced interval revascularization 
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between baseline CCTA and last follow-up than controls (50.4% vs. 23.5%, p < 0.001), and 
the time to interval revascularization was shorter in cases, with a median of 26 (interquartile 
range 5,312) days compared to 64 (19, 199, p = 0.03) days.
Per-Patient Baseline CCTA Findings in ACS Patients and Controls
Overall, there were an average of 3.9 ± 2.5 lesions in ACS patients and 3.7 ± 2.7 lesions in 
controls (p = 0.40) (Table 1). The maximal %DS at the per-patient level was <50% for both 
ACS patients and controls (44.2 ± 26.4% vs. 33.7 ± 22.0%, p<0.001), with cases and 
controls exhibiting >50% stenosis in 34.6% vs. 19.2% and >70% stenosis in 12.8% vs. 5.1% 
respectively.
ACS patients did not differ significantly from controls by total plaque volume (289.7 
± 308.4 vs. 267.2 ± 285.7 mm3, p = 0.321), calcified (97.7 ± 136.1 vs. 109.3 ± 164.0 mm3, p 
=0.389), or fibrous plaque volumes (126.8 ± 131.6 vs. 41.4 ± 62.2 mm3, p = 0.137), but had 
significantly higher fibro-fatty (58.7 ± 85.8 vs. 41.4 ± 62.2 mm3, p = 0.009) and necrotic 
core volumes (6.5 ± 14.0 vs. 4.2 ± 8.8 mm3, p = 0.026). These findings remained consistent 
when plaque volumes were normalized to vessel volume. The maximal cross-sectional 
plaque burden was also significantly higher in cases than controls (66.1±25.8 vs. 56.5±28.7, 
p<0.001), with no significant difference in the mean plaque burden.
ACS patients exhibited HRP more frequently than controls (52.1% vs. 33.3%, p = 0.003) in 
addition to each component of HRP, including LAP, PR, and SC (all p < 0.05). ACS patients 
exhibited greater atherosclerotic plaque diffuseness, but did not differ from controls in 
atherosclerotic plaques at sites of vessel bifurcation or at tortuous points within the vessel 
(all p>0.05).
Per-Patient Baseline Atherosclerotic Plaque Precursors of ACS Events
In marginal Cox regression analysis adjusting for angina severity and interval 
revascularization, highest %DS severity was an indicator of future adverse event (HR 1.010 
for every 1% increase in stenosis, 95% CI 1.005 to 1.015, p = 0.002), as well as the presence 
of high-grade coronary stenosis ≥70% (HR 1.536, 95% CI 1.141–2.067, p = 0.005, Table 2).
At the patient level, neither total plaque volume nor mean plaque burden was associated with 
an increased hazard of ACS occurrence (all p>0.05). However, fibro-fatty, necrotic core 
plaque and the sum of both were significant predictors for ACS (For every 1 mm3 increase 
respectively, HR 1.002, 95% CI 1.000 – 1.004, p = 0.048; HR 1.013, 95% CI 1.003 – 1.022, 
p = 0.009; and HR 1.002, 95% CI 1.000 –1.003, p = 0.037). Calcified and fibrous plaque 
volumes were not associated with ACS (all p>0.05). The maximal cross-sectional plaque 
burden was also significantly associated with ACS (HR 1.008 for every %, 95% CI 1.003 –
1.013, p = 0.003).
The presence of HRP was associated with ACS (HR 1.593, 95% CI 1.219 – 2.082; p = 
0.001), as were its constituents LAP (HR 1.378, 95% CI 1.051 – 1.805, p = 0.020) and SC 
(HR 1.543, 95% CI 1.169 – 2.037; p = 0.002). PR trended toward association with ACS 
(p=0.085).
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Per-Lesion Baseline Atherosclerotic Plaque Precursors of ACS Culprit Lesions
Of the 162 patients with ICA available for culprit lesion adjudication, there were 129 cases 
where the culprit lesion by ICA could be aligned to a baseline lesion by CCTA with lesion 
measurements. The duration of time between baseline CCTA and follow-up ICA was 
median (IQR) of 0.08 (0.008, 1.42) years. In 21 cases, the culprit lesion aligned to normal 
segments on the baseline CCTA with no lesion measurements, and in the remaining 12 
patients, the baseline lesion by CCTA could not be measured due to artifact or small vessel 
size. Over three-quarters of the 129 culprit lesion precursors exhibited <50% stenosis in the 
baseline CCTA (38.27 ± 20.97%), with relatively long lesions (35.90 ± 21.66 mm, Table 3). 
Overall plaque volume was 134.4 ± 141.5 mm3, which was comprised of 44.88 ± 60.29 
mm3, 58.22 ± 62.39 mm3, 28.47 ± 50.18 mm3, and 2.85 ± 9.27 mm3 of calcified, fibrous, 
fibro-fatty, and necrotic core volume, respectively (Central Illustration). The cross-sectional 
plaque burden was elevated (62.54±22.38). HRP was observed in 31.01% of culprit lesion 
precursors, and 24.03%, 76.74%, and 17.83% of culprit lesion precursors possessed LAP, 
PR, and SC, respectively.
Compared to within-subject non-culprit lesions, culprit-lesion precursors exhibited elevated 
hazard for greater %DS (HR 1.023 per % increase, 95% CI 1.015–1.031, p <0.001), lesion 
length (HR 1.021 per mm of length, 95% CI 1.013–1.029, p < 0.001), plaque volume (1.002 
per mm3 of volume, 95% CI 1.001–1.003, p<0.001) and all plaque constituents (p < 0.001 
for all), notably fibro-fatty and necrotic core volume (1.007 per mm3, 95% CI 1.003–1.010, 
p < 0.001). Culprit lesions also exhibited elevated hazard for cross-sectional plaque burden 
(1.027 per % increase, 95% CI 1.018–1.035, p<0.001), HRP (1.954, 95% CI 1.317–2.899, p 
= 0.001), LAP (1.805, 95% CI 1.198–2.721, p = 0.005), and SC (1.702, 95% CI 1.064–
2.722, p = 0.026). Comparison to between-subject control lesions with highest %DS and to 
within-subject non-culprits with highest %DS demonstrated a consistent attenuation of the 
association with %DS, calcified PV and fibrous PV (p>0.05 for all). Total plaque volume, 
mean plaque burden, fibro-fatty and necrotic core volume, and HRP exhibited elevated 
hazards with variable statistical significance depending upon the choice of control.
Discussion
In this nested case-control study from a large prospective multinational registry of patients 
undergoing CCTA, we observed measures of coronary luminal narrowing to be associated 
with but generally imprecise discriminators of future ACS. At the patient level, only 34.6% 
possessed a coronary lesion with ≥50% diameter stenosis prior to ACS, with only 12.8% 
exhibiting ≥70% stenosis. These findings were further accentuated at the lesion level 
wherein precursor lesions of culprit plaques were identified as causing ≥50% and ≥70% 
luminal obstruction only 24.8% and 4.7% of the time, respectively.
One major limitation of the extant literature on vulnerable plaque characterization is that its 
predictive value has not accounted for the denominator of atherosclerotic disease burden in 
the vulnerable patient (7,24). Our study fills an important knowledge gap as case and control 
patients were propensity matched for major patient-level characteristics including clinical 
risk factors and number of obstructive coronary vessels, and did not differ by total plaque 
volume or mean plaque burden. We observed that lesion morphology, inclusive of cross-
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sectional plaque burden, HRP, LAP, PR and SC, and plaque burden by composition, had 
independent predictive value for ACS, above and beyond clinical risk factors and total 
atherosclerotic disease burden.
Our per-lesion level results underline the complementary importance of atherosclerotic 
disease burden in relation to plaque morphology and composition. In unmatched analyses, 
culprit lesion precursors compared to other lesions within case patients displayed increased 
plaque volume, greater length, as well as greater %DS, cross-sectional plaque burden, 
composition-specific plaque volumes, and prevalence of HRP. When compared to between-
patient control lesions or within-patient non-culprit lesions with the highest luminal 
narrowing, the association with calcified and fibrous plaque volumes was weakened. Thus, 
atherosclerotic plaque burden is an important marker of lesions at risk, but controlling for 
plaque burden there is independent prognostic value of plaque features and composition. 
Additionally, within a single patient or compared to a control, future culprit lesions share 
many common features with baseline stenotic lesions, but the presence of lesions with high 
risk plaque features and fibrofatty or necrotic core demarcate risk on a per-lesion and per-
patient level.
Our results confirm the findings of prior landmark studies using invasive coronary 
angiography, demonstrating that although %DS is a strong indicator of future adverse 
events, only a minority of ACS culprit lesion precursors cause significant coronary artery 
luminal narrowing prior to ACS occurrence, even with a shorter duration between baseline 
CCTA and ICA (25,26). Our results additionally confirm the association of ACS with 
findings posited by pathologic and invasive imaging studies, including plaque volumes, 
necrotic and fibro-fatty plaque compositions, and HRP features (3,5). In the PROSPECT 
study, the sole multicenter prospective study of vulnerable plaque characteristics to date, 
among patients undergoing a repeat PCI in nearly all cases for increasing angina as their 
clinical presentation, the baseline intravascular ultrasound predictors of future ACS included 
minimum luminal area, cross-sectional plaque burden, and thin cap fibroatheroma (5,27). 
Our study found congruent results with %DS, cross-sectional plaque burden, and HRP 
findings associated with thin cap fibroatheroma including LAP (28). Our study findings 
extend the scope of these pathologic and invasive studies to a primary prevention population, 
with ACS rather than angina outcomes, and using a matched case:control population 
wherein differences in coronary luminal and atherosclerotic plaque features would be 
expectedly causal to the event (5,27). Finally, in the largest international multicenter cohort 
of ACS patients, our results demonstrate the prognostic value and generalizability of 
noninvasive plaque evaluation across a broad array of countries, CCTA scanners and 
protocols, and strengthens prior observations with invasive studies in that the majority of our 
outcome events were myocardial infarctions, and not unstable or increasing angina.
Prior CCTA studies have similarly evaluated the importance of atherosclerotic plaque 
features for prognosticating ACS. Limited to single centers, these studies have nevertheless 
highlighted the benefit of morphologic coronary assessment of LAP, PR and SC(4,9,10). Our 
study extends these pioneering studies by demonstrating the predictive value of noninvasive 
plaque quantitation by composition as well as morphology. We also highlight the 
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significance of cross-sectional plaque burden in CCTA evaluation, which has previously 
been emphasized only in the invasive imaging literature.
Our observation of gradations of risk within categories of non-calcified plaque, most notably 
for fibro-fatty and necrotic volumes, integrates the literature correlating CCTA plaque 
composition to pathology and invasive imaging. Current generation CCTA lacks the spatial 
resolution to visualize fibrous cap thickness to characterize thin cap fibroatheroma; hence, 
CCTA plaque evaluation must rely on methods that focus on luminal, vessel remodeling, and 
plaque composition using HU thresholds, such as HU<30, that are associated with necrotic 
core, and morphologic HRP criteria such as LAP, SC and PR that are associated with thin 
cap fibroatheroma (28,29). Thresholds for calcium, necrotic core, and intermediate degrees 
of fibrous tissue have largely been validated against virtual histology-intravascular 
ultrasound (VH-IVUS), but against the gold standard of histopathology, the HU of necrotic 
core and fibrous plaque demonstrates significant overlap (19,30). Conversely, the low risk of 
calcified plaque is consistent with VH-IVUS studies demonstrating that transformation of 
non-calcified plaques to calcified plaques is associated with a more benign prognosis (31). 
The implication for CCTA patient evaluation is that there is a continuum of risk by plaque 
composition, with greater weight for lower attenuation plaque burden than calcified or 
higher attenuation noncalcified plaque.
Taken together, the aforementioned findings allow several conclusions to be drawn at both 
the lesion and patient level. First, coronary luminal narrowing is a prognostic indicator of 
future ACS, but a threshold of ≥50% has low sensitivity for patients and lesions that will 
result in ACS, highlighting the need for additional or improved markers of risk. 
Furthermore, the present data support that within a patient, it is the lesion with greatest 
overall PV as well as fibro-fatty and necrotic core PV that has the greatest probability of 
becoming a culprit ACS lesions, but not necessarily the one displaying the highest %DS. 
From the results of this study, when aiming to discriminate a patient as having risk or no risk 
of ACS, it appears essential to integrate atherosclerosis feature findings with consideration 
of PV and presence of HRPs. Second, consistent with the dynamic nature of HRP and the 
frequent observation of clinically silent healed ruptures, we observed a relatively low 
sensitivity of HRP of 69% to predict a culprit lesion on a per-lesion basis, with a higher 
sensitivity on a per-patient basis. We posit that atherosclerotic plaque features represent a 
dimension of disease burden that may better identify at-risk patients on a whole patient 
basis. That is, individual plaque imaging may signal more information about the patient than 
about the individual lesion or the total plaque burden alone. Finally, we observed that in 21 
of the 162 patients with ICA available, the culprit lesion aligned to normal segments on the 
baseline CCTA. This may represent baseline non-obstructive plaque below the spatial 
resolution of CCTA, interval rapid plaque progression, or mechanisms of acute coronary 
events other than plaque rupture, such as plaque erosion. Our study design did not prescribe 
repeat CCTA, but prospective studies with serial CCTA are needed to address plaque 
progression in previously normal segments.
Our study is not without limitations. First, derived from a large observational cohort study, 
these present findings are susceptible to unmeasured confounding factors, and referral bias 
and potential biases in propensity matched controls. Indications for CCTA were for 
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evaluation of CAD in clinically stable patients, as the CONFIRM registry included many 
patients from non-US sites and with CCTAs prior to the introduction of appropriate use 
criteria. However, use of the existing cohort study allowed collection of the largest 
international multicenter cohort of atherosclerotic plaque precursors to ACS to date. Second, 
to ensure proper adjudication of ACS events, we censored patients who died without 
confirmatory findings of ACS. Thus, these findings should be considered limited to patients 
at risk of experiencing non-fatal ACS and future studies should now be performed to 
determine whether the present findings apply to fatal ACS. Missing adjudication data may 
also contribute to information bias. Third, propensity score matching on the likelihood of 
ACS results in well-matched controls with complete and careful CCTA measurements but 
reduces generalizability to the general pool of patients undergoing CCTA (Online Appendix 
VIII). Prediction models will require prospective cohorts in a generally low-risk population 
and, given the time and costs of quantitative CT, may be economically feasible only with 
completely automated CCTA measurements or deep learning. Fourth, atherosclerotic 
quantification and characterization was performed only on a single baseline CCTA. Thus, 
information related to atherosclerosis progression or transformation as related to time to 
ACS occurrence remains unknown.
Conclusions
Despite advances in risk stratification, acute coronary syndromes remain burdensome and 
unpredictable, and an integrated evaluation of vulnerable plaque identifies the vulnerable 
patient above and beyond the clinical risk factors and aggregate plaque burden. In this 
multicenter case-control study of stable patients without known CAD, the majority did not 
possess high-grade coronary stenosis before experiencing ACS. Coronary atherosclerotic 
precursors of ACS exhibited elevated fibro-fatty and necrotic core volumes, but not total or 
calcified volumes. HRP and its features of LAP, PR, and SCs, as well as cross-sectional 
plaque burden, also identify lesions and patients that will experience ACS. Both on a per-
plaque as well as per-patient basis, perhaps of greatest import is the finding of the robust 
incremental prognostic information when accounting for the atherosclerotic plaque features 
that contribute to a coronary stenosis rather than just the stenosis itself. Our data suggest a 
potential paradigm shift wherein targeted treatment of patients and lesions possessing high-
risk atherosclerotic plaque characteristics may improve therapeutic precision and outcomes. 
Future studies addressing this approach now appear warranted.
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CI Confidence interval
DS Diameter Stenosis
FF Fibro-fatty
HRP High-risk plaque
HU Hounsfield Unity
ICA Invasive coronary angiography
IVUS Intravascular ultrasound
LAP Low-attenuation plaque
MACE Major adverse cardiac events
NC Necrotic core
NSTEMI Non-ST-elevation myocardial infarction
PB Plaque burden
PR Positive remodeling
PV Plaque volume
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STEMI ST-elevation myocardial infarction
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Appendix I. ICONIC study organization and list of participating sites and 
investigators
Executive committee: James K. Min, MD, Leslee J Shaw, MD, Renu Virmani, MD, Habib 
Samady, MD, Peter Stone, MD; Jagat Narula, MD; Fay Y. Lin, MD; Daniel Berman, MD; 
Matthew Budoff, MD
Clinical and Data Coordinating Center (CDCC): Subhi J. Al-Aref, MD; Iksung Cho, MD; 
Ibrahim Danad, MD; Aeshita Dwivedi, MD; Kimberly Elmore, MS; Donghee Han, MD; 
Ran Heo, MD; Ji-Hyun Lee, MD; Mahn-won Park, MD; Wijnand Stuijfzand, MD; Jessica 
Pena, MD; Asim Rivzi, MD; Hilary Soohoo, BA; Shenghao Chen, BA; Katie An, BA; 
Richard A Ferraro, MEd; Dan Gebow, PhD.
Data management and biostatistical analysis: Heidi Gransar, MSc; Yao Lu, MSc; Amit 
Kumar, MSc; Ji Min Sung, PhD
Clinical Events Adjudication Committee: Fay Y. Lin, MD; Lohendran Bhaskaran, MD, 
Iksung Cho, MD; Ibrahim Danad, MD; Donghee Han, MD; MD; Ji-Hyun Lee, MD; Joshua 
Schulman-Marcus, MD
CCTA Core Laboratory: Hyuk-Jae Chang, MD; Hyung-Bok Park, MD; Sang-Eun Lee, MD
Study sites, principal investigators, and primary study coordinators:
• Ottawa University of Ottawa Heart Institute: Benjamin Chow, MD; Owen 
Clarkin
• William Beaumont Hospital, City, Michigan, USA: Gilbert Raff, MD; Kavitha 
Chinnaiyan, MD; Ralph Gentry and Mark Pica
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• Giovanni XXIII Hospital of Monastier/Academic Hospital of Parma: Filippo 
Cademartiri, MD PhD and Erica Maffei, MD
• German Heart Center Munich, Munich, Germany: Martin Hadamitzky, MD; 
Hanna Nieberler
• Severance Cardiovascular Hospital, Seoul, South Korea; Hyuk-Jae Chang, MD 
PhD; Sang-Eun Lee, MD
• Walter Reed Medical Center, Washington DC, USA: Todd Villines, MD
• Seoul National University Hospital, Seoul, South Korea: Yong-Jin Kim, MD 
PhD, Taekyeong Kim, MD.
• University of British Columbia, Vancouver, BC, Canada: Jonathon Leipsic, MD
• Innsbruck Medical University, Innsbruck, Austria: Gudrun Feuchtner, MD; 
Fabian Plank, MD; Harald G. Weirich, MD
• Baptist Hospital of Miami, Miami, Florida, USA: Ricardo Cury, MD; Cindy 
Stephens
• University of Milan, Centro Cardiologico Monzino, IRCCS Milan, Italy; Daniele 
Andreini, MD and Gianluca Pontone, MD; Edoardo Conte, MD
• UNICA, Hospital Da Luz, Lisbon, Portugal: Hugo Marques, MD
• Leiden University Medical Center, HARTZ, Leiden, the Netherlands: Jeroen 
Bax, MD PhD and Alexander van Rosendael, MD
Appendix II: Inclusion and exclusion criteria
• Inclusion criteria
– 13 sites in North America, Europe and Asia
– Baseline coronary computed tomographic angiography (CCTA) 
performed with prospective clinical data collection
– Had follow-up for ACS events
• Exclusion Criteria
– Cases and controls
♦ Death before acute coronary syndrome (ACS)
♦ Prior coronary artery disease (CAD)
♦ CCTA images missing or uninterpretable for core lab 
quantitative CCTA measurement
– Patient Cases
♦ Insufficient data to adjudicate
♦ Did not meet MONICA/WHO definition of ACS
Chang et al. Page 15
J Am Coll Cardiol. Author manuscript; available in PMC 2019 June 05.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
♦ ACS occurred prior to CCTA
♦ Culprit lesion in segment with interval revascularization 
(percutaneous coronary intervention (PCI) or coronary artery 
bypass graft(CABG))
– Patient Controls
♦ Not propensity matched 1:1 to adjudicated case
Appendix III. Propensity scoring
Propensity score methods
The propensity score was derived from CONFIRM registry data of 15 sites that originally 
agreed to participate in ICONIC in 2012. Patients were eligible for the propensity score 
derivation cohort if they had follow-up for ACS events, and were either ACS events or 
nonevents. Patients with deaths were censored. Matching factors were determined a priori 
and all variables forced into propensity scoring using logistic regression were used to predict 
ACS in the main model. Factors entered into the score included age, gender, hypertension, 
hyperlipidemia, diabetes, family history, current smoking, and site-interpreted baseline CAD 
severity on CCTA categorized as nonobstructive<50%, single vessel obstructive, two vessel 
obstructive, and three vessel/left main obstructive >=50%. Relaxed propensity scores with 
variables dropped were additionally derived using the same cohort to allow assignment of a 
propensity score to all ACS in the presence of missing data. Balance of covariates was 
checked by deciles. Discrimination of the propensity score was evaluated with area under the 
receiver operating curve (AUC).
Propensity score results
The propensity score derivation patient population consisted of 24,600 patients with 861 
ACS over 3.2 ± 1.9 years (Table 1--1). The full propensity score exhibited an area under the 
receiver-operating curve (AUC) of 0.94 (95% CI 0.92, 0.95, Figure III-1).
Table III-1
Full propensity score for likelihood of ACS
Univariate Multivariate
Variable OR ( 95 CI) P OR (95 CI) P
Age 1.0 (1.0–1.1) <0.001 1.0 (1.0–1.0) <0.001
Male Gender 1.6 (1.4–1.8) <0.001 1.1 (1.0–1.3) 0.12
HTN 1.7 (1.5–2.0) <0.001 1.1 (0.9–1.3) 0.039
HL 1.3 (1.1–1.5) <0.001 0.9 (0.7–1.0) 0.001
DM 2.0 (1.7–2.3) <0.001 1.3 (1.1–1.6) 0.35
FH 1.1 (0.9–1.3) 0.23 1.1 (0.9–1.3) 0.23
Current TOB 1.2 (1.1–1.5) 0.009 1.2 (1.0–1.5) 0.023
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Univariate Multivariate
Variable OR ( 95 CI) P OR (95 CI) P
CAD Severity:
 Normal/Non-Obs 1.00 1.00
 1 VD 5.5 (4.6–6.5) <0.001 4.6 (3.8–5.6) <0.001
 2 VD 6.6 (5.3–8.1) <0.001 5.1 (4.1–6.4) <0.001
 3 VD/LM 9.5 (7.8–11.6) <0.001 6.9 (5.5–8.6) <0.001
HTN: hypertension. HL: hyperlipidemia. DM: diabetes. FH: family history. TOB: tobacco (smoking). VD: vessels diseased 
(obstructive ≥50%). LM: left main.
Figure III-1. 
Propensity score distribution of candidate cases and controls prior to match
Propensity match methods
Site-adjudicated ACS cases were matched 1:1 with propensity-matched within-site controls 
from site-adjudicated nonevents stratified on site. Nearest-neighbor matching by propensity 
score was performed with a greedy matching technique to match all cases without 
replacement. A caliper width of 0.05 was used for matching.1 Cases with missing 
CONFIRM data were matched to within-site controls using relaxed propensity scores, and 
the relaxed score was assigned as the summary propensity score. The same scores and 
technique were used to identify within-site controls for additional sites that subsequently 
joined the ICONIC study. Iterative rematching of within-site controls out of remaining 
unmatched non-events was performed when control CCTA DICOM images could not be 
obtained or control CCTA measurements could not be performed due to artifact, so that all 
centrally-adjudicated ACS would have matching propensity-matched controls with CCTA 
measurements. Finally, site-adjudicated ACS that did not meet criteria for centrally-
adjudicated ACS or lacked CCTA measurements were excluded, as were their matched 
controls. With matching, the summary propensity score of AUC of candidate cases and 
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matched controls was 0.50 (95% CI 0.45, 0.55, Figure III-2). There was no significant 
difference between propensity scores in the CDCC-adjudicated cases and controls (0.07 
± 0.04 vs 0.07 ± 0.04, p = 0.73).
Figure III-2. 
Propensity score distribution of the 234 case:control pairs in the ICONIC study
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Appendix IV. Event adjudication
Event adjudication was performed by six physicians (IC, LB, DH, JL, AR, FL) blinded to 
CCTA results, with two physician arbitrations of ambiguous cases. Symptoms of ischemia 
relied upon site report Cardiac enzyme, electrocardiogram (ECG), and invasive coronary 
angiography (ICA) data were used to adjudicate and classify candidate cases as ST-segment 
elevation myocardial infarction (STEMI), non-ST-segment elevation myocardial infarction 
(NSTEMI), or unstable angina (UA) using the WHO/MONICA third universal definition of 
myocardial infarction (MI).1,2 Additionally, cases were adjudicated as unclassified MI in the 
presence of abnormal cardiac enzymes (>99% local upper limit of normal), the presence of 
other supporting information, and an ambiguous adjudication ECG unable to definitively 
classify STEMI/NSTEMI.
Cases that were adjudicated to be events other than STEMI, NSTEMI, unclassified MI or 
UA (i.e. myocarditis, Takotsubo cardiomyopathy, and congestive heart failure) were 
excluded. Cases that lacked cardiac enzyme data or had cardiac enzymes but insufficient 
clinical evidence of ischemia to determine adjudication were excluded.3
Chang et al. Page 18
J Am Coll Cardiol. Author manuscript; available in PMC 2019 June 05.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
Additionally, all cases including MI and UA were classified by etiologic type modified from 
the third universal definition of MI as follows: 1) Type 1, Spontaneous ACS; 2) Type 2, ACS 
secondary to an ischemic imbalance; 3) Type 3 (ACS resulting in death when biomarkers 
were unavailable); (4) Type 4a (ACS related to PCI); (5) Type 4b (ACS related to stent 
thrombosis); and (6) Type 5 (ACS related to CABG), when culprit was in a bypass graft.1 
ACS of Types 4a, 4b and 5 were then excluded as events that could not be related to the 
lesions evaluated during baseline CCTA.
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Appendix V. Culprit lesion precursor determination
ICA determination of culprit lesions
Sites performed ICA in accordance with typical clinical indications and imaging standards 
set forth by the American College of Cardiology/Society for Cardiac Angiography and 
Intervention.1 ICA images were transmitted to independent masked readers at the CDCC, 
who evaluated ICA to determine culprit lesions, segments and vessels using an 18-segment 
Society of Cardiovascular Computed Tomography (SCCT) model of the coronary tree.2 The 
SCCT model was chosen for ICA evaluation in order to align with the same model used for 
CCTA measurements (Figure V-I).
The Rule Out Myocardial Infarction approach by employing a Computer Assisted 
Tomography (ROMICAT) definition was used to determine culprit lesions by ICA. In ACS 
patients with a single significant stenosis, this lesion was considered the culprit lesion. In 
ACS cases with ≥2 significant lesions, the culprit lesion was defined on the basis of ICA (by 
the most severely narrowed lesion, or the lesion with the most complex morphology, or both) 
and ECG (by distribution of ischemia).3,4 In ambiguous cases or cases with multiple 
candidate culprits, a consensus reading with a second cardiologist was performed. All other 
lesions were deemed non-culprit lesions.
CCTA alignment of ICA-determined culprit lesions to CCTA precursors
Subsequent to CL CCTA analysis, ICA-identified culprit lesions were co-registered to the 
lesions (D.H. and F.Y.L.) by comparison of coronary segment coding and using distance 
from ostia and coronary vessel branch points as fiduciary landmarks. Un-blinded 
comparison of ICA and CCTA was allowed for alignment of discrepancies but not for 
reclassification of ACS.
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Figure V-1. Society of Cardiovascular CT 18-segment Coronary Tree
The same model was applied to both ICA and CCTA in order align baseline CCTAs with 
follow-up culprit lesions by ICA.
Figure V-2. Determination of culprit lesion by ICA
Blinded adjudication determined the presence of a culprit lesion in the proximal left anterior 
descending (LAD) artery by the presence of a single significant stenosis on the ICA at the 
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time of downstream ACS. Subsequently unblinded comparison was performed to align the 
culprit location to the culprit lesion precursor in the proximal LAD in the baseline CCTA.
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Appendix VI. CCTA definitions
CCTA acquisition and quality assurance
Baseline CCTA referral, performance, and site interpretation had been performed in 
accordance with each site’s institutional policy prior to initiation of the ICONIC study.1,2 
Scans were performed using ≥64-detector row single- or dual-source scanners, with multiple 
vendors, using both prospective and retrospective gating. CCTA scan parameters including 
tube current (mA), tube voltage (kV), dose-length product and contrast dose were recorded 
by individual sites. Site-submitted DICOM files for cases and controls were transmitted to 
the CCTA imaging core lab.
The CCTA imaging core lab performed quantitative and qualitative measurements of CCTA 
utilizing semi-automated plaque analysis software (MEDIS QAngio CT Research Edition 
v2.1.9.1, Medis Medical Imaging Systems, Leiden, the Netherlands, Figure VI-I), with 
reconstructions at the smallest slice thickness (e.g., ~500 μm), as previously described.3,4 
Standard displays (e.g., width 740 Hounsfield Unit (HU), level 220 HU) were adjusted by 
contrast level of the aorta (155% and 65% mean luminal intensity of central aorta). The 
presence of atherosclerosis was defined as any tissue >1mm2 within or adjacent to the lumen 
that can be discriminated from surrounding pericardial tissue, epicardial fat, or lumen; and 
identified in >2 planes.5 Independent level III-experienced readers analyzed each CCTA on a 
per-segment level, masked to clinical and test results. Measurements were then summarized 
on a per-patient level.
Consistency for interobserver and intraobserver variability of total plaque volume and 
plaque composition was maintained with biweekly QC and QA compared to other core lab 
readers and intravascular ultrasound. The interobserver and intraobserver intraclass 
correlation for total plaque volume was 0.992 and 0.996 (p<0.001 respectively). The 
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interobserver and intraobserver intraclass correlation for plaque composition ranged from 
0.95–0.99 (Table VI-1)
Per-segment basis
Segments classified by an 18-segment SCCT model were qualitatively evaluated for the 
presence and categorical stenosis severity of CAD.1,6,7 Quantitative segment analysis was 
performed for length, vessel volume (VV, mm3), lumen volume, and plaque volume (PV, 
mm3).8–10 Volumes of each plaque type were measured based on HU thresholds including: 
1) calcified plaque (HU>350), 2) fibrous plaque (HU 131–350), 3) fibrofatty plaque (HU 
31–130), and 4) necrotic core (HU −30-30).3,4
Per-lesion basis
Lesions, which did not necessarily conform to segment boundaries, were qualitatively 
evaluated for the following adverse plaque characteristics: 1) low attenuation plaque (LAP) 
defined by HU<30; 2) positive remodeling (PR), defined by remodeling index ≥1.1; 3) 
spotty calcification (SC) defined as a visually detectable calcification ≤3mm in any direction 
within a plaque, 4) napkin-ring sign, defined as a ringlike morphology of noncalcified 
plaque with a circumferential region of hyperattenuated plaque surrounding a region of 
hypoattenuation with HU<70 5) plaque composition as none, non-calcified (>70% non-
calcified), mixed (30–70% non-calcified or calcified), and calcified (>70 calcified), 6) 
bifurcation as present if it was present within 5mm of the lesion, with no distinction between 
bifurcation and trifurcation, and 7) tortuosity, defined as positive if one >90-degree bend or 
three 45–90 degree curves were found using a 3-point angle within the lesion.8,11–15 High-
risk plaque (HRP) was defined as the presence within a coronary lesion of ≥2 features 
including PR, LAP, or SC.
Quantitative lesion analysis was performed for plaque and vessel lengths and volumes 
similar to the segment analysis. In addition, the maximally stenotic cross-section was 
measured for minimal luminal area, minimal and maximal plaque thickness, and plaque 
area. The site of maximal stenosis was chosen semi-automatically by the quantitative CT 
program using the minimal lumen area within a highlighted lesion with subsequent manual 
correction. Cross-sectional plaque burden was defined as plaque area at the maximally 
stenotic cross-section/vessel area at the maximal stenotic cross section × 100 (%). Stenosis 
severity was calculated in comparison to the normal reference vessel size, defined by an 
average of the 5 mm proximal to and 5 mm distal to the lesion boundaries with manual 
correction for to the nearest normal reference cross-section in the case of branch vessels and 
tandem lesions.16 Luminal area was measured by planimetry and used to calculate the 
geometric mean diameter for estimates of diameter stenosis severity. The remodeling index 
was calculated in comparison to the proximal vessel area 5mm proximal to the lesion, again 
with manual correction for branch vessels and tandem lesions.11
Chronic total occlusions and patients with no plaque qualitatively identified on per-segment 
analysis could not undergo lesion measurements using QAngioCT but were assigned % 
diameter stenosis of 100% and 0% respectively.
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Per-patient basis
After vessel volume (VV, mm3) and plaque volume (PV, mm3) of all coronary segments 
were obtained,17 they were summated to generate PV and VV on a per-patient and per-
lesion level. For all continuous per-lesion and per-segment variables, we calculated maxima, 
minima, and sums on a per-patient basis. For all categorical per-lesion and per-segment 
variables, we calculated counts and binary presence.
Mean plaque burden (PB) was defined as [(total PV/total VV) × 100] (%).17 A segment 
involvement score was calculated, as we have previously described,18 which summates the 
total number of coronary segments with any atherosclerotic plaque. A segment stenosis 
score was similarly calculated, with each coronary segment graded in ordinal fashion 
between 0–3 based upon the severity of stenosis, and summated to yield a total per-patient 
score.18 Diffuseness of atherosclerosis was calculated as a % of the summed length of 
coronary lesions divided by the total vessel lengths.
Figure VI-1. 
Medis QAngio-CT measurement with center-plane reformat of coronary artery.
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Table VI-1
CCTA Core Lab inter- and intra-observer variability with QAngio-CT
Inter Interobserver ICC* P value Intraobserver ICC* P value
Plaque volume 0.992 <0.0001 0.996 <0.001
Calcified PV 0.996 <0.0001 0.998 <0.001
Fibrous PV 0.969 <0.0001 0.992 <0.001
Fibro-Fatty PV 0.984 <0.0001 0.988 <0.001
Necrotic Core PV 0.946 <0.0001 0.996 <0.001
*
ICC: Intra-class correlation coefficient
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Appendix VII. Additional statistics
Table VII-1
Baseline clinical characteristics of the ICONIC study.
Variables
ACS Case (n= 234)
N(%) or Mean±SD
Control (n= 234)
N(%) or Mean±SD P-value**
Age, year* 62.2 (11.5) 62.4 (10.4) 0.567
Male, %* 149 (63.7) 146 (62.4) 0.532
Risk factors*
 Hypertension, % 148 (63.2) 143 (61.1) 0.497
 Dyslipidemia, % 129 (55.1) 123 (52.6) 0.477
 Diabetes, % 46 (19.7) 74 (31.6) <0.001
 Smoking (current or past combined) 110 (47.0) 87 (37.2) 0.216
 Premature family history CAD, % 94 (40.2) 87 (37.2) 0.174
CAD severity (site read)*
 None 15 (6.4) 28 (12.0)
0.101
 Nonobstructive 47 (20.1) 91 (38.9)
 1-vessel obstructive 78 (33.3) 41 (17.5)
 2-vessel obstructive 35 (15.0) 37 (15.8)
 3-vessel/left main 48 (20.5) 37(15.8)
Propensity Score 0.07(0.04) 0.07(0.04) 0.728
Race/Ethnicity 0.467
 White 111 (47.9) 111 (47.4)
 East Asian 53 (22.6) 53 (22.6)
 Others 12 (5.1) 14 (6.0)
Body Mass Index, kg/m2 27.6 (5.1) 27.2 (4.6) 0.537
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Variables
ACS Case (n= 234)
N(%) or Mean±SD
Control (n= 234)
N(%) or Mean±SD P-value**
Angina type, % 0.004
 Asymptomatic, % 37 (15.8) 75 (32.1)
 Non-cardiac, % 28 (12.0) 32 (13.7)
 Atypical angina, % 94 (40.2) 83 (35.5)
 Typical angina, % 63 (26.9) 37 (15.8)
Dyspnea, % 40 (17.1) 47 (20.1) 0.396
Medications
 Statin 96 (41) 84 (35.9) 0.211
 ASA/Clopidogrel, % 93 (39.7) 86 (36.8) 0.710
 Warfarin (Coumadin), % 9 (3.8) 12 (5.1) 0.564
 ACE-I/ARB, % 32 (13.7) 38 (16.2) 0.475
 Beta blocker, % 63 (26.9) 67 (28.6) 0.491
 Nitrates, % 11 (4.7) 8 (3.4) 0.317
Lipid profile
 Total, mg/dl 193.1 (48.3) 186.3 (52.2) 0.317
 LDL, mg/dl 117.7 (41.7) 112.5 (37.3) 0.434
 HDL, mg/dl 47.8 (13.6) 46.7 (15.2) 0.353
 Triglycerides, mg/dl 118.6 (105.0) 132.0 (83.0) 0.269
Coronary Artery Calcium Score (site read) 0.241
 0 29 (12) 30 (13)
 1–100 36 (15) 41 (18)
 101–400 39 (17) 24 (18)
 >400 44 (19) 31 (13)
Follow-up duration, year 3.9 (2.7) 3.8 (2.4) 0.971
Interval revascularization 118 (50.4) 55 (23.5) <0.001
Time to any revascularization 0.8 (1.4) 0.6 (0.8) 0.033
ACS due to revascularization N/A N/A N/A
ACM post ACS 16 (6.8) N/A N/A
CCTA Scanner Type 0.004
 64 slice, % 101 (43.2) 91 (38.9)
 Dual source, % 78 (33.3) 89 (38.0)
 Other, % 38 (16.2) 31 (13.2)
Contrast dose 89 (16) 87 (14) 0.10
Prospective Gating 30 (12.8) 6 (2.6) 0.56
ma 673.1 (232.8) 678.4 (200.6) 0.12
kV 118.5 (29.2) 115.5 (8.9) 0.20
DLP 784.6 (438.7) 702.3 (445) 0.28
Dose in millisieverts 11.0 (6.1) 9.8 (6.2) 0.28
Case Characteristics
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Variables
ACS Case (n= 234)
N(%) or Mean±SD
Control (n= 234)
N(%) or Mean±SD P-value**
 STEMI 40 (17.1) N/A N/A
 NSTEMI 114 (48.7) N/A N/A
 MI, non-specified 6 (2.6) N/A N/A
 UA 74 (31.6) N/A N/A
Time to first event
 < 2 weeks 76 (32.5) N/A N/A
 2wks – 6 months 63 (26.9) N/A N/A
 6 mo–1 year 21 (9.0) N/A N/A
 1–2 year 26 (11.1) N/A N/A
 ≥ 2 years 48 (20.5) N/A N/A
MI location by EKG
 Anterior 25 (10.7) N/A N/A
 Inferior 17 (7.3) N/A N/A
 Posterolateral 13 (5.6) N/A N/A
 Indeterminate/other 166 (70.9) N/A N/A
*
components of the propensity score
**
Paired comparisons with Wilcoxon rank-sum for categorical and paired t-test for continuous
CAD: coronary artery disease.
Table VII-2
Per-patient comparison of additional baseline plaque characteristics.
Variables
ACS Case (n= 234)
N(%) or Mean±SD
Control (n= 234)
N(%) or Mean±SD P-value**
Segment Stenosis Score (0–48) 6.8 (4.9) 6.5 (5.3) 0.324
Segment Involvement Score (0–16) 5.3 (3.1) 5 (3.4) 0.373
Presence of napkin ring sign, n (%) 14 (6) 9 (3.8) 0.400
Table VII-3
Per-patient comparison in baseline CCTA restricted to those who underwent interval PCI
Atherosclerotic feature
ACS underwent interval 
revasc (n= 118)
N(%) or mean±SD
Control underwent interval 
revasc (n= 55)
N(%) or mean±SD p-value
Age, year* 62.2 (10.8) 65.5 (8.9) 0.097
Male, %* 81 (68.6) 36 (65.5) 0.676
Case Characteristics
 STEMI 27 (22.9)
 NSTEMI 57 (48.3)
 MI, non-specified 5 (4.2)
 UA 29 (24.6)
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Atherosclerotic feature
ACS underwent interval 
revasc (n= 118)
N(%) or mean±SD
Control underwent interval 
revasc (n= 55)
N(%) or mean±SD p-value
Number of total lesions 4.2 (2.5) 5.1 (2.5) 0.022
Diameter stenosis, % 45.1±23.6 47.7±20.5 0.550
 %DS ≥50% 42 (35.6) 21 (38.2) 0.742
 %DS ≥70% 13 (11) 7 (12.7) 0.743
Area stenosis, % 64.3±24.9 68.5±19.7 0.549
Minimum luminal area, mm2 2.1±1.6 1.7±1.0 0.355
Minimum luminal diameter, mm 1.3±0.6 1.2±0.5 0.577
CAD severity by number of vessels 0.004
 None 5 (4.2) 1 (1.8)
 Nonobstructive (≤50% DS) 11 (9.3) 15 (27.3)
 1VD 53 (44.9) 13 (23.6)
 2VD 36 (30.5) 15 (27.3)
 3VD/left main disease 13 (11) 11 (20)
Total plaque volume, mm3 311.3±295.3 464.2±346.7 0.003
 Calcified, mm3 115.2±152.7 183.5±229.5 0.031
 Fibrous, mm3 138.2±128.9 187.6±142.4 0.015
 Fibro-fatty, mm3 52.8±63 84.4±94.3 0.075
 Necrotic core, mm3 5.2±11.5 8.7±11.9 0.039
 Fibro-fatty + necrotic core, mm3 58±69.4 93.1±103.2 0.077
 Noncalcified, mm3 196.2±176.1 280.7±217.6 0.014
Composition by % vessel volume
 % Calcified 5.0±6.8 6.8±7.1 0.031
 % Fibrous 5.7±4.6 7.4±4.9 0.025
 % Fibro-fatty 2.2±2.3 3.4±3.7 0.119
 % Necrotic core 0.2±0.7 0.3±0.5 0.045
 % Fibro-fatty + necrotic core 2.4±2.7 3.7±4 0.099
 % Noncalcified volume 8.1±6.3 11.1±7.9 0.023
Mean plaque burden, % 13.1±11.1 17.9±10.8 0.003
Diffuseness, % 25.8±19.4 33.3±18.0 0.163
Adverse plaque characteristics
 Bifurcation, number of lesions 2.3±1.6 2.9±1.8 0.067
 Tortuous vessels, number of lesions 0.1±0.4 0.1±0.4 0.459
 High-risk plaque present 72 (61) 28 (50.9) 0.210
 Low-attenuation plaque present 58 (49.2) 28 (50.9) 0.830
 Positive remodeling present 107 (90.7) 50 (90.9) 0.961
 Spotty calcification present 44 (37.3) 11 (20) 0.023
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Table VII-4
Comparison of ACS case patients with and without aligned culprit lesions
Atherosclerotic feature
ACS with culprit lesion (n= 
162)
N(%) or mean±SD
ACS without identified culprit 
(n= 72)
N(%) or mean±SD p-value
Age, year* 61.5±11.3 63.8±11.9 0.245
Male, %* 108 (66.7) 41 (56.9) 0.153
Case Characteristics 0.075
 STEMI 32 (19.8) 8 (11.1)
 NSTEMI 70 (43.2) 44 (61.1)
 MI, non-specified 5 (3.1) 1 (1.4)
 UA 55 (34) 19 (26.4)
Number of total lesions 4.3±2.6 3.2±2.3 0.006
Diameter stenosis, % 46.3±24.8 39.4±29.3 0.017
 %DS ≥50%
 %DS ≥70%
Area stenosis, % 65.1±24.9 54.8±31 0.017
Minimum luminal area, mm2 2.1±1.8 2.8±2.6 0.174
Minimum luminal diameter, mm 1.3±0.6 1.5±0.8 0.139
CAD severity by number of vessels 0.059
 None 6 (3.7) 9 (12.5)
 Nonobstructive (≤50% DS) 15 (9.3) 6 (8.3)
 1VD 71 (43.8) 33 (45.8)
 2VD 54 (33.3) 15 (20.8)
 3VD/left main disease 16 (9.9) 9 (12.5)
Total plaque volume, mm3 312.4±329.3 238.5±250 0.086
 Calcified, mm3 106.4±143.7 78.2±115.9 0.045
 Fibrous, mm3 137.8±139.7 102.1±108.4 0.046
 Fibro-fatty, mm3 61.7±92.4 52±68.7 0.409
 Necrotic core, mm3 6.5±13.4 6.4±15.3 0.732
 Fibro-fatty + necrotic core, mm3 68.2±101.5 58.4±80.5 0.4
 Noncalcified, mm3 206±221.3 160.5±171 0.1
Composition by % vessel volume
 % Calcified 4.5±6.1 3.3±5.1 0.027
 % Fibrous 5.6±4.7 4.2±4.1 0.019
 % Fibro-fatty 2.4±3.1 2.1±3 0.332
 % Necrotic core 0.3±0.7 0.3±0.6 0.641
 % Fibro-fatty + necrotic core 2.7±3.5 2.4±3.5 0.322
 % Noncalcified volume 8.3±7.4 6.6±6.8 0.049
Mean plaque burden, % 12.8±11.2 9.8±10 0.035
Diffuseness, % 0.3±0.2 0.2±0.2 0.005
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Atherosclerotic feature
ACS with culprit lesion (n= 
162)
N(%) or mean±SD
ACS without identified culprit 
(n= 72)
N(%) or mean±SD p-value
Adverse plaque characteristics
 Bifurcation, number of lesions 2.4±1.6 1.9±1.4 0.032
 Tortuous vessels, number of lesions 0.1±0.3 0.1±0.3 0.321
 High-risk plaque present 89 (54.9) 33 (45.8) 0.198
 Low-attenuation plaque present 72 (44.4) 29 (40.3) 0.552
 Positive remodeling present 148 (91.4) 57 (79.2) 0.009
 Spotty calcification present 53 (32.7) 19 (26.4) 0.333
Appendix VIII. Differences between nested case-control and non-analyzed 
eligible cohort patients
After exclusion of prior CAD and death without antecedent ACS, there were 583 site-
adjudicated ACS events and 22,217 non-events. After exclusion of cases that did not meet 
criteria for core-lab adjudicated ACS, had ACS attributable to segment revascularized after 
the baseline CCTA, or lacked CCTA measurements, and after matching of controls, there 
remained 234 core lab adjudicated analyzable cases and controls. The comparison of 
analyzed cases and controls can be seen in Appendix VII.
Those analyzed in the final ICONIC cohort did not differ from excluded candidate ACS 
events by propensity score, race, CAD severity or interval revascularization (Table VIII-I). 
However, there were significant differences in some clinical predictors including lower rates 
of diabetes and higher rates of family history, current smoking, and angina severity, and 
baseline statin usage.
As expected by the propensity-matched study design, analyzed non-events were significantly 
higher risk compared to excluded non-events by propensity score, by factors included in the 
propensity score including risk factors and CAD severity, and by interval revascularization 
(Table VIII-I). Correspondingly, cardiac medication usage was generally higher in analyzed 
than excluded non-events.
Table VIII-1
Difference between analyzed and excluded patients, by ACS event status
Eligible Site-adjudicated ACS 
events
N = 583
P-value
Eligible Site-adjudicated non-
events
N = 22217
P-value
Analyzed
N=234
N(%) or Mean±SD
Excluded
N = 349
N(%) or 
Mean±SD
Analyzed
N = 234
N(%) or 
Mean±SD
Excluded
N = 21,983
N(%) or 
Mean±SD
Propensity Score 0.07±0.04 0.07±0.05 0.447 0.07±0.04 0.03±0.03 <0.001
Age 62.2±11.5 62.7±11.4 0.851 62.4±10.4 56.4±11.8 <0.001
Women 36.3% 35.5% 0.845 37.6% 45.2% 0.020
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Eligible Site-adjudicated ACS 
events
N = 583
P-value
Eligible Site-adjudicated non-
events
N = 22217
P-value
Analyzed
N=234
N(%) or Mean±SD
Excluded
N = 349
N(%) or 
Mean±SD
Analyzed
N = 234
N(%) or 
Mean±SD
Excluded
N = 21,983
N(%) or 
Mean±SD
CAD RF:
 Hypertension 63.8% 61.5% 0.569 61.1% 47.7% <0.001
 Hyperlipidemia 55.6% 53.0% 0.542 52.6% 49.0% 0.281
 Diabetes 19.7% 28.5% 0.016 31.6% 16.4% <0.001
 FH 41.2% 31.5% 0.017 37.3% 30.9% 0.033
 Current smoking 30.8% 22.1% 0.018 23.5% 17.5% 0.015
CAD severity: 0.446 <0.001
 None 6.7% 10.3% 12.0% 42.0%
 Nonobs 21.1% 21.8% 15.8% 37.8%
 1vd 35.0% 31.5% 38.9% 12.3%
 2vd 15.7% 18.2% 17.5% 4.8%
 3vd/LM 21.5% 18.2% 15.8% 3.2%
Race: 0.113 0.363
 White 63.3% 69.0% 62.4% 57.1%
 East Asian 29.9% 28.3% 29.8% 34.4%
 Other 6.8% 2.7% 7.9% 8.5%
Angina type: 0.009 0.066
 Asymptomatic 16.7% 28.5% 33.0% 39.3%
 Noncardiac 11.7% 7.5% 14.1% 11.7%
 Atypical angina 43.2% 39.0% 36.6% 37.3%
 Typical angina 28.4% 24.9% 16.3% 11.8%
Dyspnea 21.9% 19.3% 0.492 26.3% 21.5% 0.123
Medications:
 Statins 58.5% 42.0% 0.001 50.6% 32.5% <0.001
 ASA/Clopidogrel 53.1% 47.7% 0.256 48.9% 34.3% <0.001
 Warfarin 8.6% 10.4% 0.616 11.0% 5.4% 0.011
 ACEI/ARB 37.9% 38.8% 0.859 35.8% 27.5% 0.015
 Beta blocker 36.2% 32.2% 0.387 38.1% 29.5% 0.013
 Nitrates 8.9% 9.4% 0.874 6.3% 9.2% 0.260
Follow-up (years) 3.9±2.7 4.3±2.6 0.034 3.8±2.4 3.3±2.0 0.007
Interval revasc 24.8% 28.9% 0.270 23.5% 7.7% <0.001
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PERSPECTIVES
Competency in Medical Knowledge
Although acute coronary syndrome is associated with stenosis severity, most precursors 
of ACS cases and culprit lesions are non-obstructive. Noninvasive plaque evaluation, 
including CCTA evaluation of high-risk plaque, plaque composition, and cross-sectional 
plaque burden, independently predict first ACS beyond stenosis severity and aggregate 
plaque burden.
Translational Outlook
Quantitative measurement of plaque composition, as well as high-risk plaque evaluation 
and cross-sectional plaque burden, should be investigated for risk stratification in future 
cohort studies.
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Figure 1. CONSORT Diagram for the ICONIC study
ACS, acute coronary syndrome; CAD, coronary artery disease; CDCC, The Clinical and 
Data Coordinating Center; CTA, coronary computed tomography angiography; MACE, 
major adverse cardiac event
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Central Illustration. Precursors of ACS and controls as identified by CCTA
A. Adjudicated first ACS cases with CCTA measurements (n = 234) of a nested case-control 
cohort of 25,251 patients undergoing CCTA exhibit elevated fibro-fatty and necrotic core 
volumes (65.2 ± 95.4 mm3); 34.6% exhibit diameter stenosis ≥50% and 52.1% exhibit high-
risk plaque. B. Non-event controls propensity matched by demographics, risk factors, and 
number of obstructive vessels by CCTA exhibit lesser fibro-fatty and necrotic core volumes 
(45.6 ± 68.8, multivariate adjusted p = 0.008) with no difference in calcified or total plaque 
volumes (p = NS for all); %DS and HRP are significantly decreased in control patients 
(p<0.05 for all). C. Culprit lesion precursors exhibit elevated fibro-fatty and necrotic core 
volumes (31.32 ± 55.5 mm3). D. Within-patient controls, using the non-culprit with the 
highest baseline %DS, exhibit lesser total plaque and necrotic core volumes (p<0.05 for 
both). E. Between-patient controls, using the lesion with the highest %DS in the control 
patient, exhibit lesser non-calcified plaque components (p = 0.04), but no decrease in 
calcified plaque volume (p = NS). ACS, acute coronary syndrome; CCTA, coronary 
computed tomographic angiography; %DS, percent diameter stenosis; HRP, high-risk 
plaque; NS, nonsignificant.
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Table 1
CCTA findings in patient-level analysis
Atherosclerotic feature ACS (n= 234) N(%) or mean±SD Control (n= 234) N(%) or mean±SD p-value
Number of total lesions 3.9 (2.5) 3.7 (2.7) 0.400
Diameter stenosis, % 44.2±26.4 33.7±22.0 <0.001
 %DS ≥50% 81 (34.6) 45 (19.2) <0.001
 %DS ≥70% 30 (12.8) 12 (5.1) 0.007
Area stenosis, % 61.9±27.2 51.2±27.9 <0.001
Minimum luminal area, mm2 2.3±2.1 2.6±1.9 0.014
Minimum luminal diameter, mm 1.3±0.7 1.5±0.6 0.004
CAD severity by number of vessels 0.020
 None 15 (6.4) 34 (14.5)
 Non-obstructive (≤50% DS) 104 (44.4) 91 (38.9)
 1-vessel disease 69 (29.5) 59 (25.2)
 2-vessel disease 25 (10.7) 21 (9.0)
 3-vessel/left main disease 21(9.0) 29 (12.4)
Total plaque volume, mm3 289.7±308.4 267.2±285.7 0.321
 Calcified, mm3 97.7±136.1 109.3±164.0 0.389
 Fibrous, mm3 126.8±131.6 112.3±119.3 0.137
 Fibro-fatty, mm3 58.7±85.8 41.4±62.2 0.009
 Necrotic core, mm3 6.5±14.0 4.2±8.8 0.026
 Fibro-fatty + necrotic core, mm3 65.2±95.4 45.6±68.8 0.008
 Noncalcified, mm3 192.0±207.8 157.9±173.6 0.030
Composition by % vessel volume
 % Calcified 4.1±5.9 4.5±6.2 0.709
 % Fibrous 5.2±4.6 4.5±6.2 0.067
 % Fibro-fatty 2.3±3.0 1.7±2.5 0.011
 % Necrotic core 0.3±0.7 0.2±0.4 0.039
 % Fibro-fatty + necrotic core 2.6±3.5 1.9±2.7 0.012
 % Noncalcified volume 7.8±7.2 6.5±6.7 0.020
Mean plaque burden, % 11.9±10.9 11.0±10.7 0.152
Max cross-sectional plaque burden, % 66.1±25.8 56.5±28.7 <0.001
Diffuseness, % 25.8±19.4 22.3±19.2 0.030
Adverse plaque characteristics
 Bifurcation, # of lesions 2.3±1.6 2.1±1.7 0.218
 Tortuous vessels, # of lesions 0.08±0.34 0.05±0.28 0.477
 High-risk plaque present 122 (52.1) 78 (33.3) 0.003
 Low-attenuation plaque present 101 (43.2) 64 (27.4) <0.001
 Positive remodeling present 205 (87.6) 187 (79.9) 0.026
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Atherosclerotic feature ACS (n= 234) N(%) or mean±SD Control (n= 234) N(%) or mean±SD p-value
 Spotty calcification present 72 (30.8) 47 (20.1) 0.013
ACS, acute coronary syndrome; CAD, coronary artery disease; %DS, diameter stenosis; HRP, high-risk plaque; LAP, low-attenuation plaque; PR, 
positive remodeling; PV, plaque volume; SC, spotty calcification; SD, standard deviation
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Table 2
Per-patient Multivariate Marginal Cox Model Predicting Acute Coronary Syndrome
Atherosclerotic feature Hazard Ratio (95% Confidence Interval)* P
Highest % diameter stenosis severity, per % 1.010 (1.005, 1.015) 0.002
 Presence of ≥50% diameter stenosis 1.437 (0.948, 2.179) 0.088
 Presence of ≥70% diameter stenosis 1.536 (1.141, 2.067) 0.005
Plaque volume, per mm3 1.000 (0.999, 1.000) 0.792
 Calcified 0.999 (0.998, 1.000) 0.092
 Fibrous 1.000 (0.999, 1.001) 0.941
 Fibro-fatty 1.002 (1.000, 1.004) 0.048
 Necrotic core 1.013 (1.003, 1.022) 0.009
 Fibro-fatty and necrotic core 1.002 (1.000, 1.003) 0.037
 Non-calcified 1.000 (1.000, 1.001) 0.352
Mean plaque burden, % 1.005 (0.997, 1.013) 0.209
Max cross-sectional plaque burden, % 1.008 (1.003, 1.013) 0.003
Diffuseness, per % 1.146 (0.622, 2.111) 0.662
High-risk plaque present 1.593 (1.219, 2.082) 0.001
Low-attenuation plaque present 1.378 (1.051, 1.805) 0.020
Positive remodeling present 1.401 (0.955, 2.056) 0.085
Spotty calcification present 1.543 (1.169, 2.037) 0.002
*Adjusted for angina severity and interval revascularization
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